EQUALY
Equaly develops a technology platform that modulates immune responses using antigen-specific cells of the innate immune system for cancer, infectious diseases, and autoimmune disease therapies.
Equaly's technology platform modulates immune responses based on antigen-specific cells of the innate immune system, opening the door to better biologicals and new immunotherapies. The company unlocks the therapeutic potential of the innate immune system by triggering specific responses in immune cells that can both exert direct effects and modulate the adaptive immune system's response.
Key People
- Jean Marie Saint Remy - Founder – CEO & CSO